Last reviewed · How we verify
Anti-CD19 iCAR NK Cells
CD19-targeting chimeric antigen receptor (CAR) T cells
CD19-targeting chimeric antigen receptor (CAR) T cells Used for Relapsed or refractory B-cell malignancies.
At a glance
| Generic name | Anti-CD19 iCAR NK Cells |
|---|---|
| Sponsor | Allife Medical Science and Technology Co., Ltd. |
| Drug class | CAR T cell therapy |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
CD19-targeting chimeric antigen receptor (CAR) T cells are genetically modified T cells that recognize and bind to CD19, a protein expressed on the surface of B cells, and induce cell death.
Approved indications
- Relapsed or refractory B-cell malignancies
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD19 iCAR NK Cells CI brief — competitive landscape report
- Anti-CD19 iCAR NK Cells updates RSS · CI watch RSS
- Allife Medical Science and Technology Co., Ltd. portfolio CI